TITLE

Breath of Fresh Air for Spiriva

PUB. DATE
February 2010
SOURCE
Pharmaceutical Representative;Feb2010, Vol. 40 Issue 2, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the review of the U.S. Food and Drugs Administration (FDA) that long-acting respiratory treatment Spiriva HandiHaler from Boehringer Ingelheim Inc. does not raise the possibility of heart attack, death and risk of stroke in patients.
ACCESSION #
47994303

 

Related Articles

  • CNS News Round-Up.  // PharmaWatch: CNS;Apr2010, Vol. 9 Issue 4, p2 

    The article offers news briefs related to pharmaceutical companies in the U.S. Boehringer Ingelheim Inc. reported that the Food and Drug Administration (FDA) has approved its Mirapex ER extended-release tablets. Novartis AG revealed that the federal agency has granted priority review for its...

  • Parkinson's Disease Update.  // PharmaWatch: CNS;Apr2010, Vol. 9 Issue 4, p7 

    The article offers an update on the treatment of Parkinson's disease in the U.S. The Food and Drug Administration (FDA) has given approval on Boehringer Ingelheim Parkinson's drug Mirapex ER extended release tablets and made Abbreviated New Drug Application approval for the drug ropinirole...

  • FDA Issues Final Rule to Phase Out All Chlorofluorocarbon Inhalers.  // American Family Physician;5/15/2010, Vol. 81 Issue 10, p1193 

    The article reports on the phase out of all chlorofluorocarbon (CFC) inhalers by 2013, according to the U.S. Food and Drug Administration.

  • Zone in on: Regulation. Drakulich, Angie // Pharmaceutical Technology;May2010, Vol. 34 Issue 5, p25 

    The article discusses the move of the U.S. Food and Drug Administration (FDA) to phase-out the seven remaining chlorofluorocarbons (CFC)-containing inhalers on the market.

  • FDA: Act now to replace Primatene Mist inhalers.  // Pharmacy Today;Nov2011, Vol. 17 Issue 11, p2 

    The article offers information on the initiative of the U.S. Food and Drug Administration (FDA) to replace Primatene Mist inhalers such as Combivent Inhalation Aerosol inhalers and Maxair Autohaler after December 31, 2011.

  • Two asthma inhalers left gasping for life. Newman, Elizabeth // McKnight's Long-Term Care News;Jul2013, Vol. 34 Issue 7, p22 

    The article informs that the U.S. Food and Drug Administration (FDA) has phased out two asthma inhalers including the Combivent Inhalation Aerosol and the Maxair Autohaler as they contain chlorofluorocarbons (CFCs) which damage the environment.

  • OTC Metaproterenol.  // Clinical Pediatrics;Jul1984, Vol. 23 Issue 7, p397 

    This article focuses on how metaproterenol metered-dose mist inhalers were available over the counter (OTC) briefly, after the U.S. Food and Drug Administration (FDA) decided in October 1982 to allow manufacturers to switch them from prescription to OTC status. This change was made without a...

  • Guide on counters for metered-dose inhalers.  // Medical Marketing & Media;Feb2002, Vol. 37 Issue 2, p30 

    Reports on the draft guidance for metered-dose inhalers by the U.S. Food and Drug Administration. Number of dose actuations; Mechanisms of rescue bronchodilators; Quality of life.

  • FDA guidance on inhalation drug containers.  // Medical Marketing & Media;Sep2002, Vol. 37 Issue 9, p34 

    Reports on the issuance by the U.S. Food and Drug Administration of a guidance on the potential entry of chemical contaminants into inhalation drug products. Content of the guidance; Factors contributing to the accumulation of contaminants in inhalation drug products; Importance of packing on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics